Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Bone Marrow Sampling and Transplants01:22

Bone Marrow Sampling and Transplants

324
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
324
Lineage Commitment01:21

Lineage Commitment

3.0K
Commitment is the  process whereby stem cells:
3.0K
Human Genetics01:28

Human Genetics

559
Human genetics provides a profound framework for understanding the interplay between genetic predispositions and human psychology. At the heart of this discipline lies the study of how genes influence physical traits, behaviors, and susceptibility to diseases. Each person carries a unique genetic code that subtly or significantly shapes their psychological and behavioral landscape.
The complex relationship between genetics and psychology is observable through common biological components such...
559
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Mutations01:39

Mutations

81.9K
Overview
81.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Long-term follow-up of oral decitabine/cedazuridine plus venetoclax for older or unfit patients with newly diagnosed acute myeloid leukemia.

Haematologica·2026
Same author

Risk Prognostication After Hypomethylating Agents Combined With Venetoclax in AML: The PRISM Risk Model.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Vibecotamab for measurable residual disease in acute myeloid leukemia and for myelodysplastic syndromes and chronic myelomonocytic leukemia after hypomethylating agent failure: a phase II study.

Journal of hematology & oncology·2026
Same author

Investigational clinical trial agents versus conventional second salvage therapies in patients with relapsed/refractory acute myeloid leukemia.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

Final analysis of phase 2 clinical trial of ruxolitinib and azacitidine combination therapy in patients with myelodysplastic syndrome/myeloproliferative neoplasms.

Journal of hematology & oncology·2026
Same author

Prognostic and therapeutic implications of BRAF mutations in acute myeloid leukemia.

Leukemia·2026

Related Experiment Video

Updated: Jun 25, 2025

Identifying DNA Mutations in Purified Hematopoietic Stem/Progenitor Cells
11:06

Identifying DNA Mutations in Purified Hematopoietic Stem/Progenitor Cells

Published on: February 24, 2014

13.1K

Germline Predisposition in Hematologic Malignancies: Testing, Management, and Implications.

Lucy A Godley1, Courtney D DiNardo2, Kelly Bolton3

  • 1Robert H. Lurie Comprehensive Cancer Center, Division of Hematology/Oncology, Northwestern University, Chicago, IL.

American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting
|May 20, 2024
PubMed
Summary
This summary is machine-generated.

Germline DNA variants increase myeloid malignancy risk. Genetic testing, now more accessible and covered by insurance, enables personalized cancer surveillance and potential prevention strategies for affected individuals.

More Related Videos

Engineering Oncogenic Heterozygous Gain-of-Function Mutations in Human Hematopoietic Stem and Progenitor Cells
12:04

Engineering Oncogenic Heterozygous Gain-of-Function Mutations in Human Hematopoietic Stem and Progenitor Cells

Published on: March 10, 2023

3.6K
Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
11:15

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

24.3K

Related Experiment Videos

Last Updated: Jun 25, 2025

Identifying DNA Mutations in Purified Hematopoietic Stem/Progenitor Cells
11:06

Identifying DNA Mutations in Purified Hematopoietic Stem/Progenitor Cells

Published on: February 24, 2014

13.1K
Engineering Oncogenic Heterozygous Gain-of-Function Mutations in Human Hematopoietic Stem and Progenitor Cells
12:04

Engineering Oncogenic Heterozygous Gain-of-Function Mutations in Human Hematopoietic Stem and Progenitor Cells

Published on: March 10, 2023

3.6K
Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
11:15

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

24.3K

Area of Science:

  • Genetics
  • Oncology
  • Molecular Biology

Background:

  • Germline DNA variants are increasingly recognized as significant contributors to myeloid malignancy risk.
  • Despite existing barriers, referrals and availability for germline cancer predisposition testing are improving.
  • Inherited myeloid malignancy risk should be considered for all patients, irrespective of age at diagnosis, due to common predisposition alleles and expanding disorder recognition.

Purpose of the Study:

  • To highlight the growing importance of germline cancer predisposition testing for myeloid malignancies.
  • To discuss the facilitators and implications of germline testing in clinical practice.
  • To outline future directions in managing inherited risk for myeloid malignancies.

Main Methods:

  • DNA is obtained from cultured skin fibroblasts or hair bulbs for germline testing.
  • Cascade testing is efficiently performed using buccal swabs, saliva, or blood samples.
  • The study reviews current literature and clinical guidelines regarding germline myeloid malignancy predisposition.

Main Results:

  • Increased recognition of germline variants has improved testing referrals and availability.
  • Insurance coverage for germline testing is expanding as it's incorporated into guidelines.
  • Germline testing allows for personalized cancer surveillance, including screening for non-hematopoietic and other organ pathologies.

Conclusions:

  • Germline testing for myeloid malignancy predisposition is becoming more accessible and recognized.
  • Personalized surveillance and potential preventative strategies can be developed post-diagnosis.
  • Future research may lead to broader recommendations for germline testing in myeloid predisposition conditions.